Back

ROBO4 triggers pulmonary arterial hypertension through promoting the progressive reduction of pulmonary micro-vessels and the remodeling of distal pulmonary arterioles

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pathobiology of pulmonary hypertension Pathophysiology and Mechanisms ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Xiaozhou Zou

Zhejiang People's Hospital, Hangzhou (China)

4 More presentations in this session

Presentation thumbnail
The interaction of bone morphogenetic protein receptor type 2 and pentraxin 3 on inflammation and fibrosis: implications for pulmonary hypertension
Professor P. Liu (Tainan, TW)
Abstract Slides Video
Presentation thumbnail
Targeting alpha 5 beta 1 integrin as a therapeutic strategy to combat right ventricular dysfunction in pulmonary arterial hypertension
Miss S. Lemay (Quebec, CA)
Abstract Slides Video
Presentation thumbnail
Spatial proteomics unveils region-specific alterations in right ventricular remodeling rats under pressure overload
Ms J. Zhang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Comparative analysis of microRNA expression in idiopathic pulmonary arterial hypertension and Eisenmenger syndrome: Insights into vascular remodeling and disease progression
Doctor D. Miskowiec (Lodz, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Pathobiology of pulmonary hypertension
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Spatial proteomics unveils region-specific alterations in right ventricular remodeling rats under pressure overload
thumbnail
Congress Presentation
Successful treatment of pulmonary hypertension and right heart failure by antibody-based functional blocking of the extra-domain A of fibronectin in a preclinical animal model
thumbnail
Congress Presentation
Targeting alpha 5 beta 1 integrin as a therapeutic strategy to combat right ventricular dysfunction in pulmonary arterial hypertension

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources